Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

Improving CV and renal risk in patients with T2DM is not just about lowering glucose; it’s about how you lower glucose with SGLT2 inhibitors.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Have you switched your at-risk diabetes patients to an SGLT2 inhibitor? Join Drs. Christopher Cannon and Sam Dagogo-Jack as they answer key practice questions on reducing cardiovascular risk and renal dysfunction in patients with type 2 diabetes. Patients with type 2 diabetes have two to three times the risk of developing heart failure, particularly class III and IV. SGLT2 inhibitors are changing the way we address type 2 diabetes management in patients with multiple risk factors by reducing obesity, preventing renal dysfunction, and improving heart failure, which reduces heart failure hospitalizations.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Christopher Cannon, MD
    Education Director, Cardiovascular Innovation
    Preventive Cardiology Section, Brigham and Women’s Hospital
    Professor of Medicine, Harvard Medical School
    Boston, MA 

    Consulting Fees: Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, Rhoshan, Sanofi
    Research Grants: Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, Pfizer

    Sam Dagogo-Jack, MD, DSc
    Professor of Medicine & Director of Endocrinology, Diabetes & Metabolism
    University of Tennessee Health Science Center
    Memphis, TN 

    Consulting Fees: AstraZeneca, Janssen, Merck, Sanofi
    Contracted Research: AstraZeneca, Boehringer Ingelheim
    Ownership Interest: Aerami Therapeutics, Jana Care, Inc. 

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Nick Lombardi has disclosed ownership Interest in Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the impact that results of newer cardiovascular outcomes trials with SGLT2 inhibitors will have in determining effective combination strategies in patients with type 2 diabetes
    • Identify strategies for collaborative care models among specialties to reduce overall cardiovascular risk in this patient population
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, endocrinologists, endocrine nurse practitioners and physician assistants, and primary care providers.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free